SightfileU.S. market data from official filings

SPYGLASS PHARMA INC (SGP)

Name: SPYGLASS PHARMA INC (SGP) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001778922 · EDGAR filings · Updated 2026-05-14

SPYGLASS PHARMA INC (SGP) has reported institutional ownership of 75.8%, with 35 institutional managers holding positions valued at $655.4M per the latest 13F reporting period.

Institutional ownership

75.8%

Institutional managers

Reported 13F value

$655.4M

Insider activity

82 trans.

$221.5M net buying

Latest updates

2026-05-14 — Quarterly report (10-Q) filed
2026-05-14 — Current report (8-K) filed
2026-03-26 — Annual report (10-K) filed
2026-03-26 — Current report (8-K) filed
2026-03-09 — Current report (8-K) filed
2026-02-17 — SCHEDULE 13G filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, SPYGLASS PHARMA INC has 35 institutional holders and institutional ownership of 75.8%.

Insider activity

Insiders reported 82 transactions (17 buys, 0 sells) across 18 reporting insiders, with a net reported value of $221.5M.

Related companies

CASTLE BIOSCIENCES INC (CSTL) · BRIGHT MINDS BIOSCIENCES INC (DRUG) · GH RESEARCH PLC (GHRS) · TALKSPACE INC (TALK) · AVANOS MEDICAL INC (AVNS) · AMPHASTAR PHARMACEUTICALS INC COM (AMPH)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-05-14.